Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Lebwohl during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Arena Pharmaceuticals
- BioMX
- National Psoriasis Foundation
- American Osteopathic College of Dermatology
- Pfizer Inc.
- Focus Insight Strategic Consulting ltd
- Hexima
- Incyte Corporation
- Boehringer Ingelheim Corporation
- Brickell Biotech
- Mindera
- Trevi Therapeutics
- Vial
- Anaptys Bio
- Evommune Inc.
- Forte Biosciences
- Seanergy
- vtv therapeutics
- Verrica Pharmaceuticals
- AltruBio Inc.
- Avotres Therapeutics
- Dermavant Sciences
- Aristea Therapeutics
- National Society of Cutaneous Medicine
- Arcutis, Inc.
- Castle Biosciences
- Celltrion Inc.
- Meiji Seika Pharma
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
- American Osteopathic College of Dermatology
- New York College of Podiatric Medicine (NYCPM)
- Facilitation of International Dermatology Education (FIDE)
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- American Academy of Dermatology
- Foundation for Research and Education in Dermatology
- Corevitas
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Lebwohl during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Arena Pharmaceuticals
- BioMX
- National Psoriasis Foundation
- American Osteopathic College of Dermatology
- Pfizer Inc.
- Focus Insight Strategic Consulting ltd
- Hexima
- Incyte Corporation
- Boehringer Ingelheim Corporation
- Brickell Biotech
- Mindera
- Trevi Therapeutics
- Vial
- Anaptys Bio
- Evommune Inc.
- Forte Biosciences
- Seanergy
- vtv therapeutics
- Verrica Pharmaceuticals
- AltruBio Inc.
- Avotres Therapeutics
- Dermavant Sciences
- Aristea Therapeutics
- National Society of Cutaneous Medicine
- Arcutis, Inc.
- Castle Biosciences
- Celltrion Inc.
- Meiji Seika Pharma
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
- American Osteopathic College of Dermatology
- New York College of Podiatric Medicine (NYCPM)
- Facilitation of International Dermatology Education (FIDE)
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- American Academy of Dermatology
- Foundation for Research and Education in Dermatology
- Corevitas
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
